AstraZeneca

Summary

AstraZeneca appeared to be the Corporate Investor, which was created in 1999. The main department of described Corporate Investor is located in the Cambridge. The company was established in North America in United States.

We also calculated 29 valuable employees in our database.

The typical case for the fund is to invest in rounds with 2-3 participants. Despite the AstraZeneca, startups are often financed by Auven Therapeutics, New Enterprise Associates, Johnson & Johnson Development Corporation. The meaningful sponsors for the fund in investment in the same round are Auven Therapeutics, Redmile Group, Novartis. In the next rounds fund is usually obtained by Auven Therapeutics, Viking Global Investors, Redmile Group.

The common things for fund are deals in the range of 50 - 100 millions dollars. Considering the real fund results, this Corporate Investor is 2 percentage points less often commits exit comparing to other organizations. The high activity for fund was in 2014. Despite it in 2019 the fund had an activity. The fund is generally included in 2-6 deals every year. The average startup value when the investment from AstraZeneca is more than 1 billion dollars. The higher amount of exits for fund were in 2018. Opposing the other organizations, this AstraZeneca works on 11 percentage points less the average amount of lead investments.

Among the most successful fund investment fields, there are Health Care, Biopharma. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has exact preference in a number of founders of portfolio startups. Among the most popular portfolio startups of the fund, we may highlight Moderna Therapeutics, FibroGen, Rani Therapeutics. Besides, a startup needs to be aged 6-10 years to get the investment from the fund.